FORT LAUDERDALE, Florida

Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the upcoming presentation of an abstract regarding the Sylvester Comprehensive Cancer Center at the University of Miami proof-of-concept studies titled, Risk Stratification System for Oral Screening, at the Boston University / Dana-Farber Head & Neck Cancer Symposium, taking place in Boston, MA on September 21, 2015 at the Boston University School of Management. These studies provided direction for the clinical development of Vigilant Biosciences OncAlert™ Oral Cancer product line.

Details for the poster presentation are as follows:

Monday, September 21, 2015 8:00 AM – 5:00 PM, Metcalf Trustee Ballroom, 1 Silber Way, Boston, MA

Poster 17, “Risk Stratification System for Oral Screening,” Researchers: Lutécia H. Mateus Pereira, Isildinha M. Reis, Erika P. Reategui, Claudia Gordon, Sandra Saint-Victor, Robert Duncan, Carmen Gomez, Stephanie Bayers, Penelope Fisher, Aymee Perez, W. Jarrard Goodwin, Jennifer J. Hu, Elizabeth J. Franzmann

The schedule of events can be viewed online through the symposium website at http://www.bu.edu/dental/research/head-neck-cancer-symposium.

About the OncAlert Product Line
Vigilant Biosciences’ initial products, the OncAlert Oral Cancer RAPID Test (“OncAlert RAPID Test”) and the OncAlert Oral Cancer LAB Test (“OncAlert LAB Test”), are the first and only technologies that measure soluble CD44 and total protein levels – protein markers clinically shown to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. Both products use a simple, oral rinse collection and measurement procedure that is easy to administer and non-invasive for the patient. The accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus). The OncAlert LAB Test is CE Marked. The OncAlert RAPID Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time. The OncAlert Oral Cancer product line is not yet available for sale in the U.S.

About Oral Cancer
According to the Oral Cancer Foundation, there are over 640,000 new cases of oral cancer each year worldwide. In the U.S., close to 48,250 individuals will be diagnosed with oral or pharyngeal cancer this year, with 9,575 deaths from the disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Vigilant’s OncAlert Oral Cancer product line includes rapid and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The OncAlert Oral Cancer product line is not yet available for sale in the U.S. For more information, visit www.vigilantbiosciences.com.